Journal of Lipid Research (Mar 2005)

Apolipoprotein L-I is positively associated with hyperglycemia and plasma triglycerides in CAD patients with low HDL

  • Timothy S.E. Albert,
  • Philippe N. Duchateau,
  • Samir S. Deeb,
  • Clive R. Pullinger,
  • Min H. Cho,
  • David C. Heilbron,
  • Mary J. Malloy,
  • John P. Kane,
  • B. Greg Brown

Journal volume & issue
Vol. 46, no. 3
pp. 469 – 474

Abstract

Read online

Apolipoprotein L-I (apoL-I) is present on a subset of HDL particles and is positively correlated with plasma triglycerides (TGs). We measured plasma apoL-I levels in coronary artery disease (CAD) subjects with low HDL who were enrolled in an angiographic CAD prevention trial. At baseline, apoL-I levels (n = 136; range, 2.2–64.1 μg/ml) were right skewed with a large degree of variability. Multivariate analysis for biological determinants of apoL-I revealed that the log of VLDL-TG (+0.17; P 50% higher than normoglycemic subjects (n = 112; 13.2 vs. 8.3 μg/ml, respectively; P 50% (n = 36; P < 0.01). Genotyping of a known apoL-I polymorphism (Lys166Glu) did not independently account for any of the variability in apoL-I levels.In conclusion, we found TG and HG to be the strongest predictors of apoL-I within a dyslipidemic CAD population. These data provide further characterization of the novel HDL-associated apoL-I.

Keywords